logo

Alnylam Pharmaceuticals Inc. (ALNY)



Trade ALNY now with
  Date
  Headline
4/15/2019 7:15:57 AM Alnylam Begins ILLUMINATE-B Phase 3 Pediatric Study Of Lumasiran
4/8/2019 7:01:41 AM Regeneron And Alnylam Collaborate To Discover, Develop And Commercialize New RNAi Therapeutics
4/8/2019 1:03:11 AM Alnylam And Sanofi Conclude Research And Option Phase Of 2014 RNAi Therapeutics Collaboration
3/27/2019 7:05:11 AM Alnylam To Present Givosiran Phase 3 Data At EASL International Liver Congress
3/6/2019 7:10:28 AM Alnylam Posts Positive Topline Results From ENVISION Phase 3 Study Of Givosiran
2/7/2019 5:11:25 PM Alnylam Pharma Q4 Loss/share $2.09 Vs. Loss $1.48 Year Ago
2/6/2019 5:02:43 PM Alnylam Reports Publication Of Phase 1 Givosiran Data In The New England Journal Of Medicine
1/23/2019 8:01:15 AM CAMP4 Therapeutics Announces Rare Disease Research Collaboration With Alnylam
1/21/2019 3:11:34 AM Alnylam Pharma And Medison Pharma Partner To Commercialize RNAi Therapeutics In Israel
1/14/2019 9:25:08 PM Alnylam Pharma Prices Underwritten Public Offering Of 5 Mln Shares At $77.50/shr
1/14/2019 4:07:33 PM Alnylam Pharmaceuticals Announces Proposed Public Offering Of Common Stock
1/7/2019 8:06:51 AM Alnylam Says Maintained Strong Balance Sheet With Unaudited Year-End Cash And Investments Balance Of About $1.1 Bln
12/10/2018 2:02:07 AM Alnylam Resolves All Litigation Worldwide With Silence Therapeutics